Piper Sandler analyst Matt O’Brien raised the firm’s price target on CVRx (CVRX) to $20 from $16 and keeps an Overweight rating on the shares ...

In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Medtronic (MDT – Research Report), with a price ...

Piper Sandler analyst Matt O'Brien increased the price target for Glaukos Corporation (NYSE:GKOS) shares to $180 from the previous target of $140, while maintaining an Overweight rating on the stock.

Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the ...

Piper Sandler reaffirmed an overweight rating on Boston Scientific shares, with analyst Matt O'Brien expressing optimism for the company's performance, especially its Farapulse product.

Piper Sandler Companies (PIPR) came out with quarterly earnings of $4.80 per share, beating the Zacks Consensus Estimate of $3.62 per share. This compares to earnings of $4.03 per share a year ago.

Piper Sandler Companies reported robust financial results for Q4 2024, significantly surpassing analyst expectations. The company achieved earnings per share (EPS) of $4.80, exceeding the ...

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR) has released its most recent financial results. The complete earnings release can be found on the firm’s website at ...

Piper Sandler reported Q4 2024 adjusted net revenues ... as well as Aviditi integration. Brendan O'Brien, Wolfe Research: Asked about trends in financial services and healthcare.

Piper Sandler Companies reported robust financial results for Q4 2024, significantly surpassing analyst expectations. The company achieved earnings per share (EPS) of $4.80, exceeding the forecasted ...